Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches

Unlocking the potential of broadly reactive coronavirus monoclonal antibodies (mAbs) and their derivatives offers a transformative therapeutic avenue against severe COVID-19, especially crucial for safeguarding high-risk populations. Novel mAb-based immunotherapies may help address the reduced effic...

Descripció completa

Dades bibliogràfiques

Autors principals:	Daouda Abba Moussa, Mario Vazquez, Christine Chable-Bessia, Vincent Roux-Portalez, Elia Tamagnini, Mattia Pedotti, Luca Simonelli, Giang Ngo, Manon Souchard, Sebastien Lyonnais, Myriam Chentouf, Nathalie Gros, Soledad Marsile-Medun, Heiko Dinter, Martine Pugnière, Pierre Martineau, Luca Varani, Manel Juan, Hugo Calderon, Mar Naranjo-Gomez, Mireia Pelegrin
Format:	Artigo
Idioma:	Inglês
Publicat:	Taylor & Francis Group 2025-12-01
Col·lecció:	Emerging Microbes and Infections
Matèries:	Non-neutralizing antibodies infected cell-targeting SARS-CoV-2 antibody-based therapy cell therapy CAR-T cells
Accés en línia:	https://www.tandfonline.com/doi/10.1080/22221751.2024.2432345
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!